Your browser doesn't support javascript.
Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital.
Chauvineau-Grenier, Angélique; Bastard, Paul; Servajean, Antoine; Gervais, Adrian; Rosain, Jérémie; Jouanguy, Emmanuelle; Cobat, Aurélie; Casanova, Jean-Laurent; Rossi, Benjamin.
  • Chauvineau-Grenier A; Medical Biology Department, Robert Ballanger Hospital, Aulnay-Sous-Bois, France. angelique.grenier@ght-gpne.fr.
  • Bastard P; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Servajean A; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
  • Gervais A; University of Paris, UFR de Médecine, site Xavier Bichat, Paris, France.
  • Rosain J; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Jouanguy E; University of Paris, Imagine Institute, Paris, France.
  • Cobat A; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Casanova JL; University of Paris, Imagine Institute, Paris, France.
  • Rossi B; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
J Clin Immunol ; 42(3): 459-470, 2022 04.
Article in English | MEDLINE | ID: covidwho-1653612
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Recent studies reported the presence of pre-existing autoantibodies (auto-Abs) neutralizing type I interferons (IFNs) in at least 15% of patients with critical COVID-19 pneumonia. In one study, these auto-Abs were found in almost 20% of deceased patients across all ages. We aimed to assess the prevalence and clinical impact of the auto-Abs to type I IFNs in the Seine-Saint-Denis district, which was one of the most affected areas by COVID-19 in France during the first wave. We tested for the presence of auto-Abs neutralizing type I IFNs in a cohort of patients admitted for critical COVID-19 pneumonia during the first wave in the spring of 2020 in the medicine departments at Robert Ballanger Hospital, Aulnay sous Bois. We found circulating auto-Abs that neutralized 100 pg/mL IFN-α2 and/or IFN-ω in the plasma (diluted 1/10) of 7.9% (11 of 139) of the patients hospitalized for critical COVID-19. The presence of neutralizing auto-Abs was associated with an increased risk of mortality, as these auto-Abs were detected in 21% of patients who died from COVID-19 pneumonia. Deceased patients with and without auto-Abs did not present overt clinical differences. These results confirm both the importance of type I IFN immunity in host defense against SARS-CoV-2 infection and the usefulness of detection of auto-Abs neutralizing type I IFNs in the management of patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interferon Type I / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Language: English Journal: J Clin Immunol Year: 2022 Document Type: Article Affiliation country: S10875-021-01203-3

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Interferon Type I / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Language: English Journal: J Clin Immunol Year: 2022 Document Type: Article Affiliation country: S10875-021-01203-3